Stockreport

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting [Yahoo! Finance]

Palatin Technologies, Inc.  (PTN) 
NASDAQ:AMEX Investor Relations: palatin.com/investors/overview
PDF 71% achieved a 30% reduction in UP/Cr, a key indicator of kidney damage. 71% demonstrated improved or stabilized eGFR, signaling preserved kidney function. 37.5% ha [Read more]